Stock Fundamentals

Company Information

Company Name
Amicus Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US03152W1099
CIK: 0001178879
CUSIP: 03152W109
Currency: USD
Full Time Employees: 511
Phone: 609 662 2000
Fiscal Year End: December
IPO Date: May 31, 2007
Description:

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.

Address:

47 Hulfish Street, Princeton, NJ, United States, 08542

Directors & Officers

Name Title Year Born
Mr. Bradley L. Campbell M.B.A. CEO, President & Director 1976
Mr. Simon Nicolas Reade Harford Chief Financial Officer 1960
Ms. Ellen S. Rosenberg J.D. Chief Legal Officer & Corporate Secretary 1964
Mr. David M. Clark Chief People Officer 1976
Dr. Jeffrey P. Castelli Ph.D. Chief Development Officer 1972
Ms. Samantha L. Prout Chief Accounting Officer & Controller 1979
Dr. Jill Weimer Ph.D. Chief Science Officer NA
Mr. Andrew Faughnan Vice President of Investor Relations NA
Mr. Patrik S. Florencio Esq. Global Chief Compliance & Risk Officer NA
Mr. Brendan McEvoy Executive Director of External Communications NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 02, 2026 Bradley L Campbell N/A Sale 22.50K $14.35 $322.88K
Jan 20, 2026 Bradley L Campbell N/A Sale 75.00K $14.31 $1.07M
Dec 19, 2025 David Michael Clark N/A Sale 25.64K $14.17 $363.35K
Dec 15, 2025 Bradley L Campbell N/A Sale 77.93K $10.86 $846.28K
Dec 15, 2025 David Michael Clark N/A Sale 25.64K $11.00 $282.07K
Dec 01, 2025 Bradley L Campbell N/A Sale 14.59K $10.01 $146.02K
Nov 26, 2025 Ellen Rosenberg N/A Sale 23.62K $10.00 $236.21K
Nov 25, 2025 Ellen Rosenberg N/A Sale 36.00K $10.00 $360.00K
Nov 24, 2025 Bradley L Campbell N/A Sale 14.59K $10.04 $146.45K
Nov 24, 2025 David Michael Clark N/A Sale 25.64K $10.10 $258.99K
Nov 24, 2025 Jeff Castelli N/A Sale 76.16K $10.16 $773.77K
Nov 04, 2025 David Michael Clark N/A Sale 25.64K $9.51 $243.86K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 33.88M Mar 31, 2026 10.79% $0.01 4.17%
Vanguard Group Inc 29.70M Dec 31, 2025 9.46% $0.01 0.57%
UBS Group AG 15.96M Mar 31, 2026 5.08% $0.03 170.78%
Vanguard Capital Management, LLC 14.02M Mar 31, 2026 4.47% $0.01 0.00%
Pentwater Capital Management LP 14.00M Mar 31, 2026 4.46% $1.05 21.74%
Vanguard Portfolio Management, LLC 13.97M Mar 31, 2026 4.45% $0.01 0.00%
State Street Corp 12.89M Mar 31, 2026 4.11% $0.01 -13.07%
Glazer Capital, LLC 12.72M Mar 31, 2026 4.05% $3.90 693.29%
Fidelity International Ltd 12.56M Mar 31, 2026 4.00% $0.14 1,212.44%
The Goldman Sachs Group Inc 11.56M Mar 31, 2026 3.68% $0.02 88.12%
Qube Research & Technologies 8.81M Mar 31, 2026 2.81% $0.14 98.65%
HBK INVESTMENTS L P 8.78M Mar 31, 2026 2.80% $1.29 -42.40%
Geode Capital Management, LLC 8.54M Mar 31, 2026 2.72% $0.01 16.21%
O'Connor Alternative Investments, LLC 8.44M Mar 31, 2026 2.69% $10.46 0.00%
Millennium Management LLC 7.91M Mar 31, 2026 2.52% $0.05 164.05%
Morgan Stanley - Brokerage Accounts 7.00M Mar 31, 2026 2.23% $0.01 27.72%
JPMorgan Chase & Co 6.75M Mar 31, 2026 2.15% $0.01 81.56%
Cnh Partners, LLC 5.84M Mar 31, 2026 1.86% $1.39 194.68%
Soros Fund Management LLC 5.75M Mar 31, 2026 1.83% $0.91 15.06%
Kryger Capital LLC 4.55M Mar 31, 2026 1.45% $4.66 0.00%

Shares Statistics

Shares Outstanding: 314.00M
Shares Float: 311.44M
% Insiders: 68.60%
% Institutions: 10,438.90%
Short % Float: 7.03%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Canadian Large Cap Sr B 4.46M 1.42% ▲ 0.00% Mar 31, 2026
2 Fidelity Small Cap Index 2.91M 0.93% ▲ 0.09% Mar 31, 2026
3 Nomura US Small Cap Core Equity 2.84M 0.91% ▲ 0.00% Mar 31, 2026
4 Fidelity Global Value Long/Short F 2.58M 0.82% ▲ 0.00% Mar 31, 2026
5 Fidelity Canadian Large Cp Mlt Ast Bs O 2.12M 0.68% ▲ 0.00% Mar 31, 2026
6 Pictet Biopharmaceutical Mother 2.11M 0.67% ▲ 33.11% Oct 14, 2025
7 Fidelity Global Equity+ Fund - F8 2.09M 0.67% ▼ 0.84% Mar 31, 2026
8 Russell 2000 Equity Index Fund B 1.84M 0.59% ▲ 3.54% Dec 31, 2025
9 Xtrackers S&P 500 2xLev Dly Swap ETF 1C 1.83M 0.58% ▼ 21.56% Dec 31, 2025
10 Varenne Valeur A EUR Acc 1.79M 0.57% ▼ 0.78% Mar 31, 2026

Valuation Metrics

Enterprise Value: $4.70B
Trailing P/E: 0.00
Forward P/E: 30.49

Financial Highlights

Market Cap: $4.55B
EBITDA: $41.95M
PEG Ratio: $-0.18
Book Value: $0.88
Earnings/Share: $-0.09
Profit Margin: -4.28%
Operating Margin: 8.61%
ROA (TTM): 2.49%
ROE (TTM): -11.58%
Revenue (TTM): $634.21M
Revenue/Share (TTM): $2.06
Earnings Growth (YOY): -95.50%
Revenue Growth (YOY): 23.70%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 2.84x 1.46x 0.71x 0.75x 7.46x
2024-12-31 3.39x 2.05x 0.75x 0.50x 13.56x
2023-12-31 2.88x 2.47x 0.79x -1.54x -4.30x
2022-12-31 3.05x 3.26x 0.83x -5.71x -2.01x
2021-12-31 4.09x 1.29x 0.66x -6.36x -1.96x
2020-12-31 4.47x 1.38x 0.68x -11.01x -1.63x
2019-12-31 4.04x 0.33x 0.44x -16.11x -0.47x
2018-12-31 6.40x 0.94x 0.57x -14.68x -1.00x
2017-12-31 5.60x 0.47x 0.44x -25.64x -0.38x
2016-12-31 3.06x 0.43x 0.65x -33.70x -0.79x
2015-12-31 2.94x 0.24x 0.62x -82.66x -0.65x
2014-12-31 7.66x 0.12x 0.42x -46.29x -0.21x
2013-12-31 8.44x 0.32x 0.64x -1,395.24x -0.24x
2012-12-31 11.32x 0.01x 0.37x -594.73x -0.01x
2011-12-31 3.46x 0.04x 0.58x -343.83x -0.02x
2010-12-31 6.76x 0.04x 0.42x -214.76x -0.04x
2009-12-31 7.19x 0.05x 0.16x -26.44x -0.94x
2008-12-31 9.24x 0.03x 0.45x -201.63x -0.06x
2007-12-31 10.32x 0.03x 0.38x -131.62x -0.06x
2006-12-31 5.39x -0.05x 2.30x N/A -0.08x
2005-12-31 9.59x -0.03x 2.25x N/A -0.05x
2004-12-31 0.00x 0.00x 0.18x N/A 0.00x
2003-12-31 N/A 0.00x 11.53x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about FOLD.US!